Oak Ridge Investments LLC lessened its stake in shares of Akorn, Inc. (NASDAQ:AKRX) by 60.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 692,097 shares of the company’s stock after selling 1,037,680 shares during the period. Oak Ridge Investments LLC owned 0.55% of Akorn worth $22,971,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. OMERS ADMINISTRATION Corp acquired a new position in Akorn during the second quarter valued at approximately $31,585,000. Great West Life Assurance Co. Can grew its holdings in Akorn by 0.7% during the second quarter. Great West Life Assurance Co. Can now owns 51,847 shares of the company’s stock valued at $1,738,000 after purchasing an additional 340 shares during the last quarter. World Asset Management Inc acquired a new position in Akorn during the second quarter valued at approximately $210,000. Airain ltd grew its holdings in Akorn by 133.1% during the second quarter. Airain ltd now owns 77,070 shares of the company’s stock valued at $2,585,000 after purchasing an additional 44,011 shares during the last quarter. Finally, Alpine Associates Management Inc. acquired a new position in Akorn during the second quarter valued at approximately $8,047,000. Institutional investors own 68.67% of the company’s stock.
Several equities analysts have commented on the company. Jefferies Group LLC set a $34.00 price target on Akorn and gave the company a “hold” rating in a report on Sunday, October 29th. Zacks Investment Research upgraded Akorn from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 24th. Piper Jaffray Companies set a $34.00 price target on Akorn and gave the company a “hold” rating in a report on Sunday, October 22nd. Royal Bank Of Canada reiterated a “hold” rating and set a $34.00 price target on shares of Akorn in a report on Tuesday, October 3rd. Finally, BidaskClub downgraded Akorn from a “sell” rating to a “strong sell” rating in a report on Saturday, August 19th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $29.38.
Akorn, Inc. (AKRX) traded up $0.07 on Thursday, hitting $33.44. The stock had a trading volume of 1,158,800 shares, compared to its average volume of 2,768,830. Akorn, Inc. has a 12 month low of $17.61 and a 12 month high of $34.00. The company has a quick ratio of 3.17, a current ratio of 4.16 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $4,173.61, a PE ratio of 20.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.33.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Want to see what other hedge funds are holding AKRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akorn, Inc. (NASDAQ:AKRX).
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.